GSK’s Blenrep Hit By Trial Failure, Raising Questions About Its Future In The Myeloma Market
Phase III Study Misses Endpoint
DREAMM-3's failure does not bode well for further readouts in earlier myeloma therapy, and could even see Blenrep removed from the market. • Source: GSK
